ArticleProceedings of the National Academy of Sciences of the United States of America2012
Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 265 citations in OpenAlex.
- Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.Biomolecules · 2023Pooled it
- New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine - Pre-Clinical and Pilot Human Clinical Investigations.International journal of nanomedicine · 2020Trial
- Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms.International journal of nanomedicine · 2026Review
- Synthesis and in vitro characterization of [EJNMMI radiopharmacy and chemistry · 2025Article
- Preclinical Evaluation of Stable Integrin αPharmaceuticals (Basel, Switzerland) · 2025Article
- Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages.Materials (Basel, Switzerland) · 2025Review
- N-Heterocyclic Carbenes as Ligands toJournal of medicinal chemistry · 2025Article
- Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers.Molecular pharmaceutics · 2025Article
- In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.Journal of nanobiotechnology · 2025Review
- Influence of biopolymer based gold nanoparticles and photobiomodulation in in vitro wound healing.Scientific reports · 2025Article
- Review
- Anti-cancer Properties of Epigallocatechin-3-gallate (EGCG) and its Signaling Pathways.Current medicinal chemistry · 2025Review
- Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.EJNMMI radiopharmacy and chemistry · 2024Review
- Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [European journal of nuclear medicine and molecular imaging · 2024Article
- Article
- Doxorubicin Conjugated γ-Globulin Functionalised Gold Nanoparticles: A pH-Responsive Bioinspired Nanoconjugate Approach for Advanced Chemotherapeutics.Pharmaceutics · 2024Article
- Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm.Chemical & biomedical imaging · 2024Review
- Green Nanotechnology Through Papain Nanoparticles: Preclinical in vitro and in vivo Evaluation of Imaging Triple-Negative Breast Tumors.Nanotechnology, science and applications · 2024Article
- Nano-Ayurvedic Medicine Approaches UsingNanotechnology, science and applications · 2024Article
- Nanomedicines in diagnosis and treatment of prostate cancers: an updated review.Frontiers in bioengineering and biotechnology · 2024Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
Systemic delivery of therapeutic agents to solid tumors is hindered by vascular and interstitial barriers. We hypothesized that prostate tumor specific epigallocatechin-gallate (EGCg) functionalized radioactive gold nanoparticles, when delivered intratumorally (IT), would circumvent transport barriers, resulting in targeted delivery of therapeutic payloads. The results described herein support our hypothesis. We report the development of inherently therapeutic gold nanoparticles derived from the Au-198 isotope; the range of the (198)Au β-particle (approximately 11 mm in tissue or approximately 1100 cell diameters) is sufficiently long to provide cross-fire effects of a radiation dose delivered to cells within the prostate gland and short enough to minimize the radiation dose to critical tissues near the periphery of the capsule. The formulation of biocompatible (198)AuNPs utilizes the redox chemistry of prostate tumor specific phytochemical EGCg as it converts gold salt into gold nanoparticles and also selectively binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells. Pharmacokinetic studies in PC-3 xenograft SCID mice showed approximately 72% retention of (198)AuNP-EGCg in tumors 24 h after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 d demonstrating significant inhibition of tumor growth compared to controls. This innovative nanotechnological approach serves as a basis for designing biocompatible target specific antineoplastic agents. This novel intratumorally injectable (198)AuNP-EGCg nanotherapeutic agent may provide significant advances in oncology for use as an effective treatment for prostate and other solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.